EPALINGES

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Thursday, May 9, 2024
ADC, Conference, Webcast, Event

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m.

Key Points: 
  • LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m.
  • ET.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com .
  • A replay of the webcast will be available for approximately 30 days.

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

Retrieved on: 
Monday, May 6, 2024
Sale, Prospectus, Capital market, Guggenheim Partners, Madison Avenue, Floor, ADC, Jefferies Group, Cantor, Marketing, Attention, Therapy, Telephone, SIX Swiss Exchange, Security (finance)

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price).

Key Points: 
  • LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price).
  • The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million.
  • The offering is expected to close on May 8, 2024, subject to customary closing conditions.
  • Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Retrieved on: 
Monday, May 6, 2024
FDA, University, City, Safety, University of Miami, Doctor of Philosophy, ADC, Patient, Diffuse large B-cell lymphoma, NHL, Toxicity, Therapy, Pharmaceutical industry

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).

Key Points: 
  • LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
  • As of the data cutoff date of March 30, 2024, 15 patients were evaluable.
  • Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR).
  • “Based on the initial data from University of Miami’s Phase 2 trial evaluating ZYNLONTA in relapsed/refractory MZL, we are encouraged by the potential opportunity in the 2L+ setting for patients with this rare disease.”

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Retrieved on: 
Thursday, April 4, 2024
B-cell lymphoma, Toxicity, Associate, Part, Patient, CRS, University, Doctor of Philosophy, Therapy, Diffuse large B-cell lymphoma, Infrared spectroscopy correlation table, Division, ADC, Hematology, Cytokine release syndrome, Lymphoma, Follicular lymphoma, Pharmaceutical industry

LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Key Points: 
  • Additionally, after the first investigator assessment, evidence of anti-tumor activity was observed among the majority of patients, with mixed histologies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL).
  • “The early data from Part 1 of our LOTIS-7 trial highlight the potential combinability of ZYNLONTA with bispecifics in lymphoma patients,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • For more information about the LOTIS-7 trial, visit clinicaltrials.gov (NCT04970901).

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

Retrieved on: 
Wednesday, April 3, 2024
PIN, ADC, EDT, Therapy, Doctor of Philosophy

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT.

Key Points: 
  • LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT.
  • The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company’s novel exatecan-based antibody drug conjugate platform.
  • It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
  • A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Retrieved on: 
Monday, April 1, 2024
Employment, Compensated emancipation, Grant, Therapy

LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”).

Key Points: 
  • LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”).
  • The Grants were offered as material inducement to the employees’ employment.
  • The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company.
  • The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 13, 2024
AXL, PIN, Neutropenia, Growth, Rituximab, Sarcoma, ALT, NSCLC, ASH, FY, Progression-free survival, Skin infection, Patient, Follicular lymphoma, S&M, Research, EDT, Aes, Periodic breathing, G&A, University, Lung cancer, Insurance, AACR, DLT, Pancreatic cancer, Hyperglycemia, Society, Therapy, Clinical trial, Diffuse large B-cell lymphoma, PFS, CD22, ADC, Data, Fatigue, MD Anderson Cancer Center, FDA, DLBCL, Marketing, PSMA, IDMC, Pharmaceutical industry

LAUSANNE, Switzerland, March 13, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business updates.

Key Points: 
  • “In the fourth quarter we saw results of our strategy in action across a number of key areas.
  • A return to sequential quarter-over-quarter growth in the fourth quarter of 2023 followed the restructuring of the commercial model, with sales volume increasing in both community and academic settings.
  • R&D expenses were $30.3 million for the fourth quarter and $127.1 million for full year 2023, compared to $48.1 million and $186.5 million, respectively, for the fourth quarter and full year 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024

Retrieved on: 
Wednesday, March 6, 2024
Therapy, PIN, ADC

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m.

Key Points: 
  • LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m.
  • ET to report financial results for the fourth quarter and year ended December 31, 2023, and provide business updates.
  • It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
  • A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit

Retrieved on: 
Wednesday, March 6, 2024
Event, Webcast, Guggenheim, ADC

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.

Key Points: 
  • LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com .
  • A replay of the webcast will be available for approximately 30 days.